Safe Conversion From Tacrolimus to Belatacept in High Immunologic Risk Kidney Transplant Recipients With Allograft Dysfunction.

Trial Profile

Safe Conversion From Tacrolimus to Belatacept in High Immunologic Risk Kidney Transplant Recipients With Allograft Dysfunction.

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 May 2017

At a glance

  • Drugs Belatacept (Primary) ; Mycophenolate mofetil
  • Indications Renal transplant rejection
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 May 2017 Results (n=11) presented at the 2017 American Transplant Congress
    • 16 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top